Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium. The Phase 1 dose escalation study is being conducted in China and is enrolling participants with metastatic urothelial cancer (mUC) as well as participants with other solid tumors prospectively confirmed to have nectin-4 positive tumors. The study opened for enrollment in January 2023, and data through December 2023 from the first eighteen participants reflective of…